Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Designer Daniel Lee replaces Riccardo Tisci at Burberry

Wed, 28th Sep 2022 09:44

Former Bottega Veneta creative head joins British brand

*

Tisci steps down after nearly five years

*

Move follows arrival of new CEO earlier this year

LONDON, Sept 28 (Reuters) - Burberry Group has appointed Daniel Lee as its new chief creative officer, replacing Riccardo Tisci, who is stepping down after presenting his final runway show for the British luxury brand on Monday.

The end of Tisci's near five-year tenure at Burberry follows the arrival of Jonathan Akeroyd as new chief executive earlier this year. Chief Financial Officier Julie Brown is also leaving to join drugmaker GSK.

Lee was creative director at Italy's Bottega Veneta from 2018 to 2021, and has previously worked at Celine, Maison Margiela, Balenciaga and Donna Karan, Burberry said on Wednesday.

The 35-year-old Central Saint Martins graduate successfully ignited the Italian label's popularity with younger consumers and boosted sales with popular accessories including pillowy leather clutch handbags and slip-on heels.

He departed suddenly from the Kering-owned brand last November, just three years into his position.

Lee, born in Yorkshire where Burberry manufactures its famous trench coats, said he was honoured to join the British fashion house and build on Tisci's legacy.

Shares in Burberry rose 3.2% in early deals on Wednesday, one of the few gainers in the FTSE 100 index which was 2% lower.

Stifel analyst Rogerio Fujimori said the change should be seen as a long-term positive given Lee's successful track record in ready-to-wear.

Luca Solca at Bernstein said Lee could develop product categories such as handbags and shoes.

"So far, the British brand has struggled to make its mark in these categories and create high profile iconic products," he said. "Daniel could open this opportunity."

However, the change could also increase the level of uncertainty and perceived lack of direction, following recent departures of the CEO and CFO and as the macroeconomic situation potentially deteriorates, said Thomas Chauvet of Citi.

Tisci was the creative force behind former chief executive Marco Gobbetti's strategy to elevate the position of the 166-year-old brand in the luxury sector.

His designs, many of which featured a new Thomas Burberry "TB" monogram, strengthened the brand's streetwear offer and attracted a younger and more diverse community of customers.

Stifel's Fujimori said his collections were however "not able to create the strong buzz seen at the hottest luxury brands in the past five years", such as Dior, YSL, Bottega Veneta and Balenciaga, which Burberry needed to accelerate top-line growth. (Reporting by Paul Sandle in London, Mimosa Spencer in Paris and Yadarisa Shabong in Bengaluru; Editing by Kate Holton, Sachin Ravikumar and Emelia Sithole-Matarise)

More News
3 Jun 2024 17:19

Pharma, energy stocks drag London's FTSE 100; ECB rate cut hopes cap losses

FTSE 100 down 0.2%, FTSE 250 up 0.8%

*

Read more
3 Jun 2024 17:00

LONDON MARKET CLOSE: FTSE 100 down amid shaky start in New York

(Alliance News) - The FTSE 100 in London closed lower on Monday, marking a mixed start to June, with GSK firmly at the bottom of the index.

Read more
3 Jun 2024 14:01

GSK immunotherapy bowel cancer drug works for 100% of patients

(Alliance News) - An immunotherapy drug could spare bowel cancer patients the need for surgery and chemotherapy after results showed it was effective in 100% of cases.

Read more
3 Jun 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 up, while Labour commits to defence

(Alliance News) - Stock prices in London were up at midday, after data from S&P Global signalled a return to growth for the UK manufacturing sector.

Read more
3 Jun 2024 09:08

TOP NEWS: GSK vows to appeal adverse Delaware court ruling on Zantac

(Alliance News) - GSK PLC on Monday said it will appeal a US court ruling that it should face jury trials relating to cases concerning the heartburn drug, Zantac.

Read more
3 Jun 2024 08:37

LONDON MARKET OPEN: Stocks up amid slew of manufacturing PMIs

(Alliance News) - Stock prices in London opened higher on Monday, ahead of local purchasing managers index data, and comparative prints from several other major global economies.

Read more
3 Jun 2024 08:00

LONDON BRIEFING: FTSE 100 seen up; GSK defends ranitidine cancer claim

(Alliance News) - Stocks in London are set to open higher on Monday, ahead of a data-heavy week, kicked off by a slew of manufacturing purchasing managers' index readings.

Read more
3 Jun 2024 07:30

GSK to appeal Delaware ruling on jury trials in Zantac cancer cases

(Sharecast News) - GSK shares were down almost 10% on Monday after a US court ruled that jury trials could hear expert witnesses in 70,000 cases brought by cancer sufferers claiming its Zantac heartburn drug caused their condition.

Read more
1 Jun 2024 21:35

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
1 Jun 2024 21:07

Delaware judge lets more than 70,000 Zantac lawsuits go forward

June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer.

Read more
31 May 2024 17:45

US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label

May 31 (Reuters) - The U.S. Food and Drug Administration approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
31 May 2024 16:01

US FDA approves Moderna's RSV vaccine, its second marketed product

May 31 (Reuters) - The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.

Read more
30 May 2024 20:56

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, May 30 (Reuters) - A third U.S. dairy worker tested positive for bird flu after exposure to infected cows, and was the first to suffer respiratory symptoms, U.S. officials said on Thursday in the latest expansion of the outbreak. Bird flu has been found in dairy cattle in nine states. This second case in a Michigan dairy worker was found through increased testing of people and cows in the state following the April 1 identification of a case in a Texas farm worker. Here's what you need to know about the outbreak.

WHY IS H5N1 OR BIRD FLU A CONCERN?

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.